Gut microbiota in chronic kidney disease-mineral and bone disorder: shared mechanisms, disease-specific signatures, and therapeutic prospects - Scorecard - MDSpire
Advertisement
Gut microbiota in chronic kidney disease-mineral and bone disorder: shared mechanisms, disease-specific signatures, and therapeutic prospects
Clinical Scorecard: The Role of Gut Microbiota in Chronic Kidney Disease-Mineral and Bone Disorder: Interconnected Mechanisms, Unique Disease Markers, and Potential Treatment Strategies
At a Glance
Category
Detail
Condition
Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)
Key Mechanisms
Gut microbiota dysbiosis drives chronic low-grade inflammation, impairs intestinal barrier, promotes endotoxin translocation, alters metabolites (reduced SCFAs, accumulation of uremic toxins), and dysregulates endocrine pathways (FGF23-Klotho axis, PTH), exacerbating renal injury and abnormal bone metabolism via the gut-kidney-bone axis.
Target Population
Patients with chronic kidney disease and metabolic bone diseases including rheumatoid arthritis, osteoarthritis, and osteoporosis
Care Setting
Clinical management of CKD and metabolic bone disorders, including potential microbiota-targeted interventions
Key Highlights
Gut microbiota acts as a core regulator in the gut-kidney-bone axis influencing CKD-MBD pathogenesis.
Dysbiosis contributes to chronic inflammation and metabolic disturbances common to CKD, RA, OA, and OP.
Microbiota-targeted therapies (probiotics, prebiotics, synbiotics, dietary fiber, fecal microbiota transplantation) show promise in improving bone health and CKD outcomes.
Guideline-Based Recommendations
Diagnosis
Consider assessment of gut microbiota composition and function as part of CKD-MBD evaluation.
Monitor markers of intestinal barrier integrity and systemic inflammation linked to dysbiosis.
Management
Implement interventions targeting gut microbiota dysbiosis such as probiotics, prebiotics, synbiotics, dietary fiber supplementation, and fecal microbiota transplantation.
Address metabolic bone disease and CKD comorbidities through modulation of gut-derived metabolites and endocrine pathways.
Monitoring & Follow-up
Regularly evaluate renal function, bone metabolism markers, and inflammatory status to assess treatment efficacy.
Monitor changes in gut microbiota profiles and related metabolites (e.g., SCFAs, uremic toxins).
Risks
Dysbiosis may exacerbate systemic inflammation and metabolic disturbances, worsening CKD and bone disease progression.
Potential adverse effects or variability in response to microbiota-targeted therapies require careful clinical monitoring.
Patient & Prescribing Data
Individuals with CKD and associated mineral and bone disorders, including those with comorbid osteoarticular diseases
Microbiota-targeted interventions can modulate the gut-kidney-bone axis, reduce inflammation, and improve bone metabolism, representing a novel therapeutic avenue in CKD-MBD management.
Clinical Best Practices
Integrate gut microbiota assessment into the comprehensive evaluation of CKD-MBD patients.
Employ multi-modal microbiota-targeted therapies tailored to individual dysbiosis profiles.
Monitor systemic inflammation and metabolic markers to guide and adjust treatment strategies.
Educate patients on dietary and lifestyle modifications that support gut microbiota health.
Collaborate multidisciplinary teams including nephrologists, endocrinologists, and microbiome specialists for optimized care.
